We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Technology Differentiates Five Entamoeba Species

By LabMedica International staff writers
Posted on 06 Jun 2013
A rapid, high-throughput screening method has been developed for the simultaneous detection and differentiation of Entamoeba species.

Among the Entamoeba species, only E. More...
histolytica is considered to be pathogenic, causing intestinal and extraintestinal disease, but it is morphologically identical to E. dispar and E. moshkovskii.

Scientists at The Federal University of Rio de Janeiro (Brazil) extracted 74 DNA samples from human stools and nine of these DNA extracts were from stools that were positive for Entamoeba species by microscopy. Polymerase chain reaction (PCR) amplification was performed with biotinylated Entamoeba spp 18S ribosomal ribonucleic acid (rRNA) gene primers, designed to amplify a fragment ranging from 382 to 429 base pairs (bp) of the Entamoeba species studied.

All parasitological positive samples were tested using real-time PCR and nine stools samples were also analyzed by DNA sequencing. In addition regions of the fragments that could differentiate among E. histolytica, E. moshkovskii, E. dispar, E. hartmanii and E. coli were selected to design hybridization probes to link to Luminex beads (Austin, TX, USA). The assay was standardized with cloned DNA samples of each species and evaluated with 24 DNA extracts from samples obtained from individuals diagnosed with these amebae in their stools.

The investigators were able to correctly identify the five different species in all of the specimens studied. From the 24 samples tested by microscopy, PCR/DNA Sequencing and real-time PCR, there was 100% concordance with the PCR-Luminex assay for identification of E. dispar, E. moshkovskii, E. hartmanni, E. histolytica, and E. coli. They were able to identify samples with more than one species of Entamoeba by performing a Luminex assay and all fifty parasitologically negative stool samples were negative in the assay.

The authors concluded that that the method could be used in the diagnostic detection of Entamoeba species in fecal samples. This diagnostic test was useful to clearly distinguish the pathogenic E. histolytica from the other species and also to strengthen epidemiologic data on Entamoeba species. The study was published on March 15, 2013, in the journal Parasites & Vectors.

Related Links:

The Federal University of Rio de Janeiro

Luminex


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.